The Effect of COVID-19 Patients' Serum Phosphate Level on Mortality in ICU
Phosphate Levels of COVID-19 Patients and Mortality
1 other identifier
observational
160
1 country
1
Brief Summary
The investigators aimed to investigate the relationship between phosphate level and mortality using the 4C Mortality Score in COVID-19 patients who were followed up in the intensive care unit.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 3, 2021
CompletedFirst Submitted
Initial submission to the registry
March 10, 2021
CompletedFirst Posted
Study publicly available on registry
March 16, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 15, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
July 31, 2021
CompletedMarch 16, 2021
March 1, 2021
3 months
March 10, 2021
March 15, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
4C mortality score
4C Mortality Scores of the patients will be calculated, according to age, gender, number of comorbidities, respiratory rate, SpO2, GCS, urea, and CRP parameters
6 months
serum phosphate levels
mg/dl
6 months
mortality
mortality percentage of patients in 28 days
28 days
Interventions
4C mortality score and phosphate levels
Eligibility Criteria
Participants hospitalized in the intensive care unit diagnosed with COVID-19 will incluse in the study
You may qualify if:
- Participants hospitalized in the intensive care unit diagnosed with COVID-19 will incluse in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ankara City Hospital
Ankara, 06800, Turkey (Türkiye)
Related Publications (3)
Murer H, Forster I, Biber J. The sodium phosphate cotransporter family SLC34. Pflugers Arch. 2004 Feb;447(5):763-7. doi: 10.1007/s00424-003-1072-5. Epub 2003 May 16.
PMID: 12750889RESULTPistolesi V, Zeppilli L, Polistena F, Sacco MI, Pierucci A, Tritapepe L, Regolisti G, Fiaccadori E, Morabito S. Preventing Continuous Renal Replacement Therapy-Induced Hypophosphatemia: An Extended Clinical Experience with a Phosphate-Containing Solution in the Setting of Regional Citrate Anticoagulation. Blood Purif. 2017;44(1):8-15. doi: 10.1159/000453443. Epub 2017 Feb 21.
PMID: 28219057RESULTWang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
PMID: 32031570RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
betül aytaç, MD
ankara ch bilkent
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 6 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- medical doctor
Study Record Dates
First Submitted
March 10, 2021
First Posted
March 16, 2021
Study Start
March 3, 2021
Primary Completion
June 15, 2021
Study Completion
July 31, 2021
Last Updated
March 16, 2021
Record last verified: 2021-03